More recently, the study of Chen and colleagues provided direct evidence for CRTC1-MAML2 as a key driver for MEC development and validated CRTC1-MAML2 as a therapeutic target for patients with MEC (29). This evidence concerns the gene MAML2 and mucoepidermoid carcinoma.